Pricing Log in Create free account

Capricor Therapeutics, Inc. (CAPR) vs Entera Bio Ltd. (ENTX)

Capricor Therapeutics, Inc. and Entera Bio Ltd. are both Biotechnology companies. Capricor Therapeutics, Inc. and Entera Bio Ltd. are of similar size ($462.4M and $455.2M). Entera Bio Ltd. grew revenue faster over the last twelve months: 66.4% against −11.6%. Across the 14 metrics below, Capricor Therapeutics, Inc. leads on 8 and Entera Bio Ltd. on 6.

Valuation

Metric CAPR ENTX Biotechnology median
P/E n/m n/m 8.56
P/S 19.43 599.53 10.17
P/B 1.76 18.40 2.34
Price to free cash flow 3.31 n/m 20.42
EV/EBITDA n/m n/m 0.69
EV/Sales 9.38 534.34 9.64
Earnings yield (32.80%) (13.21%) (29.41%)
Free cash flow yield 30.25% (8.22%) (23.50%)

Profitability

Metric CAPR ENTX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (73.70%) (138.92%) (56.66%)
Return on assets (51.53%) (87.02%) (49.22%)
Return on invested capital (1,019.73%) 0.00% 0.00%

Growth

Metric CAPR ENTX Biotechnology median
Revenue growth (TTM) (11.55%) 66.42% 5.64%
EPS growth (last fiscal year) (96.52%) 0.00% 30.08%
Revenue growth, 5-year CAGR 85.83% (29.19%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR ENTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.35 8.98 4.72
Net debt to EBITDA 2.99 1.29 0.96

Dividend

Metric CAPR ENTX Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric CAPR ENTX Biotechnology median
Market cap 455.23m 462.40m 151.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack